Bernardo Matos da Cunha
Bernardo Matos da Cunha has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Bruno Silva de Araujo Ferreira
Centro Universitário Serra dos Órgãos (UNIFESO), Teresopolis, RJ, Brazil
3 shared publications Leopoldo Santos-Neto
Universidade de Brasília
2 shared publications- Luciana Pinto Valadares
Unit of Osteometabolic Disorders, SARAH Network of Rehabilitation Hospitals, Brasília, Brazil
2 shared publications Sandro Barbosa de Oliveira
Hospital SARAH, Brasília, DF, Brasil
2 shared publications- Aline Dalfito Gava
Hospital Sarah-Brasília, Sarah Network of Rehabilitation Hospitals, SMHS 301 bloco A, Zip code: 70335-901, Brasília, DF, Brazil
1 shared publication - Alí Duarte-García
Mayo Clinic Rochester Minnesota
1 shared publication
Latest Publications
- Open Access
- 19 April 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (2) , 247-255
Effects of zoledronic acid therapy in fibrous dysplasia of bone: a single-center experience
Objective: Fibrous dysplasia (FD) is a rare bone disorder that can involve any part of the skeleton, leading to bone pain, deformities, and fractures. Treatment with intravenous bisphosphonates has been used with variable results. Therefore, we aimed to evaluate the effects of zoledronic acid (ZA) therapy in patients with monostotic or polyostotic FD. Subjects and methods: The medical records of thirteen patients with FD evaluated between 2015 and 2020 were retrospectively analyzed. In the subgroup of patients treated with [...] ABSTRACT Objective: Fibrous dysplasia (FD) is a rare bone disorder that can involve any part of the skeleton, leading to bone pain, deformities, and fractures. Treatment with intravenous bisphosphonates has been used with variable results. Therefore, we aimed to evaluate the effects of zoledronic acid (ZA) therapy in patients with monostotic or polyostotic FD. Subjects and methods: The medical records of thirteen patients with FD evaluated between 2015 and 2020 were retrospectively analyzed. In the subgroup of patients treated with
- 19 April 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (2) , 247-255
Open AccessEffects of zoledronic acid therapy in fibrous dysplasia of bone: a single-center experience
Objective: Fibrous dysplasia (FD) is a rare bone disorder that can involve any part of the skeleton, leading to bone pain, deformities, and fractures. Treatment with intravenous bisphosphonates has been used with variable results. Therefore, we aimed to evaluate the effects of zoledronic acid (ZA) therapy in patients with monostotic or polyostotic FD. Subjects and methods: The medical records of thirteen patients with FD evaluated between 2015 and 2020 were retrospectively analyzed. In the subgroup of patients treated with [...] ABSTRACT Objective: Fibrous dysplasia (FD) is a rare bone disorder that can involve any part of the skeleton, leading to bone pain, deformities, and fractures. Treatment with intravenous bisphosphonates has been used with variable results. Therefore, we aimed to evaluate the effects of zoledronic acid (ZA) therapy in patients with monostotic or polyostotic FD. Subjects and methods: The medical records of thirteen patients with FD evaluated between 2015 and 2020 were retrospectively analyzed. In the subgroup of patients treated with
- Open Access
- 29 December 2021
- Published by Wiley in Journal of Osteoporosis
- Vol. 2021, 1-7
Characteristics Associated with Acute-Phase Response following First Zoledronic Acid Infusion in Brazilian Population with Osteoporosis
We aimed to evaluate characteristics associated with acute-phase response (APR) following first zoledronic acid infusion in a Brazilian cohort. This retrospective cohort study enrolled all adults with osteoporosis who underwent a first zoledronic acid infusion at our centre between June 2015 and June 2019. Clinical demographics (age, sex, diabetes, smoking, body mass index, and previous oral bisphosphonate use) and laboratory data (calcium, parathyroid hormone, renal function, and serum 25-hydroxyvitamin D and carboxy-terminal crosslinked telopeptide of type 1 collagen [CTX], both before and after infusion) were compared between patients with and without APR. We evaluated association magnitude between the presence of APR and clinical variables through logistic regression. This study enrolled 400 patients (women, 80%). APR was observed in 24.5% (n = 98) of patients. The mean symptom duration in days was 3.5 ± 2.8. Patients with APR were younger (67 ± 12 vs. 71 ± 11 years; ), used oral bisphosphonates less frequently (34% × 50%; ), and had greater baseline CTX (0.535 ng/mL [0.375, 0.697] × 0.430 [0.249, 0.681]; ) and ΔCTX (−69 [−76; −50] × −54 [−72; −23]; ) than those without APR. The other variables were similar between the groups. Only ΔCTX was associated (OR, 0.62; 95% CI 0.41–0.98) with APR after accounting for age and bisphosphonate use. APR occurred in 24.5% of the cohort. Younger age and absence of prior oral bisphosphonate use were associated with APR following first zoledronic acid infusion. APR was associated with ΔCTX (but no other variables) after adjusting for these factors.
- 29 December 2021
- Published by Wiley in Journal of Osteoporosis
- Vol. 2021, 1-7
Open AccessCharacteristics Associated with Acute-Phase Response following First Zoledronic Acid Infusion in Brazilian Population with Osteoporosis
We aimed to evaluate characteristics associated with acute-phase response (APR) following first zoledronic acid infusion in a Brazilian cohort. This retrospective cohort study enrolled all adults with osteoporosis who underwent a first zoledronic acid infusion at our centre between June 2015 and June 2019. Clinical demographics (age, sex, diabetes, smoking, body mass index, and previous oral bisphosphonate use) and laboratory data (calcium, parathyroid hormone, renal function, and serum 25-hydroxyvitamin D and carboxy-terminal crosslinked telopeptide of type 1 collagen [CTX], both before and after infusion) were compared between patients with and without APR. We evaluated association magnitude between the presence of APR and clinical variables through logistic regression. This study enrolled 400 patients (women, 80%). APR was observed in 24.5% (n = 98) of patients. The mean symptom duration in days was 3.5 ± 2.8. Patients with APR were younger (67 ± 12 vs. 71 ± 11 years; ), used oral bisphosphonates less frequently (34% × 50%; ), and had greater baseline CTX (0.535 ng/mL [0.375, 0.697] × 0.430 [0.249, 0.681]; ) and ΔCTX (−69 [−76; −50] × −54 [−72; −23]; ) than those without APR. The other variables were similar between the groups. Only ΔCTX was associated (OR, 0.62; 95% CI 0.41–0.98) with APR after accounting for age and bisphosphonate use. APR occurred in 24.5% of the cohort. Younger age and absence of prior oral bisphosphonate use were associated with APR following first zoledronic acid infusion. APR was associated with ΔCTX (but no other variables) after adjusting for these factors.
- 1 September 2021
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 49 (1) , 110-114
COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance
Objective: To describe coronavirus disease 2019 (COVID-19) and pregnancy outcomes in patients with rheumatic disease who were pregnant at the time of infection.Methods: Since March 2020, the COVID-19 Global Rheumatology Alliance has collected cases of patients with rheumatic disease with COVID-19. We report details of pregnant women at the time of COVID-19 infection, including obstetric details separately ascertained from providers.Results: We report on 39 patients, including 22 with obstetric detail available. The mean and median age was 33 years, range 24–45 years. Rheumatic disease diagnoses included rheumatoid arthritis (n = 9), systemic lupus erythematosus (n = 9), psoriatic arthritis/other inflammatory arthritides (n = 8), and antiphospholipid syndrome (n = 6). Most had a term birth (16/22), with 3 preterm births, 1 termination, and 1 miscarriage; 1 woman had yet to deliver at the time of report. One-quarter (n = 10/39) of pregnant women were hospitalized following COVID-19 diagnosis. Two of 39 (5%) required supplemental oxygen (both hospitalized); no patients died. The majority did not receive specific medication treatment for their COVID-19 (n = 32/39, 82%), and 7 patients received some combination of antimalarials, colchicine, anti–interleukin 1β, azithromycin, glucocorticoids, and lopinavir/ritonavir.Conclusion: Women with rheumatic diseases who were pregnant at the time of COVID-19 had favorable outcomes. These data have limitations due to the small size and methodology; however, they provide cautious optimism for pregnancy outcomes for women with rheumatic disease particularly in comparison to the increased risk of poor outcomes that have been reported in other series of pregnant women with COVID-19.
- 1 September 2021
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 49 (1) , 110-114
COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance
Objective: To describe coronavirus disease 2019 (COVID-19) and pregnancy outcomes in patients with rheumatic disease who were pregnant at the time of infection.Methods: Since March 2020, the COVID-19 Global Rheumatology Alliance has collected cases of patients with rheumatic disease with COVID-19. We report details of pregnant women at the time of COVID-19 infection, including obstetric details separately ascertained from providers.Results: We report on 39 patients, including 22 with obstetric detail available. The mean and median age was 33 years, range 24–45 years. Rheumatic disease diagnoses included rheumatoid arthritis (n = 9), systemic lupus erythematosus (n = 9), psoriatic arthritis/other inflammatory arthritides (n = 8), and antiphospholipid syndrome (n = 6). Most had a term birth (16/22), with 3 preterm births, 1 termination, and 1 miscarriage; 1 woman had yet to deliver at the time of report. One-quarter (n = 10/39) of pregnant women were hospitalized following COVID-19 diagnosis. Two of 39 (5%) required supplemental oxygen (both hospitalized); no patients died. The majority did not receive specific medication treatment for their COVID-19 (n = 32/39, 82%), and 7 patients received some combination of antimalarials, colchicine, anti–interleukin 1β, azithromycin, glucocorticoids, and lopinavir/ritonavir.Conclusion: Women with rheumatic diseases who were pregnant at the time of COVID-19 had favorable outcomes. These data have limitations due to the small size and methodology; however, they provide cautious optimism for pregnancy outcomes for women with rheumatic disease particularly in comparison to the increased risk of poor outcomes that have been reported in other series of pregnant women with COVID-19.
- Open Access
Patients with rheumatoid arthritis with moderate or high disease activity benefit from multidisciplinary rehabilitation: a nested case-control study
Background rheumatologists recognize the importance of rehabilitation in patients with rheumatoid arthritis (RA), but they are not confident if patients with significant disease activity would benefit from it. Objective To verify if rheumatoid arthritis patients with moderate to severe inflammatory activity (MHA) improve functional capacity (FC) after a comprehensive rehabilitation program. Methods Nested case-control study. RA patients who completed a rehabilitation program between June 2014 and December 2017 were included. The interventions were prescribed according to the rehabilitation team’s discretion. FC was assessed with Health Assessment Questionnaire Disability Index (HAQ) and compared between before and after interventions. The group which improved at least 50% in CDAI was compared to the group which achieved Results We included 46 patients with complete HAQ and baseline CDAI data, with a mean age of 53.6 years and mean disease duration of 11.8 years. HAQ and CDAI improved on average 0.481 (± 0.500) and 14.2 (± 16.7), respectively. Patients who improved CDAI tended to have a greater mean HAQ difference (0.6 vs. 0.3; p = 0.058). Conversely, patients who did not improve disease activity had a HAQ reduction of 0.3 (± 0.4). Post-hoc analysis was performed on the group of 9 patients with baseline CDAI ≤10. A mean baseline CDAI of 5.2 and a mean HAQ difference of 0.319 (0.079; 0.56; p = 0.016) were found. Conclusions After rehabilitation, RA patients with sustained MHA improved FC similarly to patients with baseline mild activity or remission. Thus, patients with RA and MHA may benefit from rehabilitation concurrently with drug treatment. This study suggests that the range of improvement in FC with rehabilitation appears to have an additive effect to the drug therapy.
Open AccessPatients with rheumatoid arthritis with moderate or high disease activity benefit from multidisciplinary rehabilitation: a nested case-control study
Background rheumatologists recognize the importance of rehabilitation in patients with rheumatoid arthritis (RA), but they are not confident if patients with significant disease activity would benefit from it. Objective To verify if rheumatoid arthritis patients with moderate to severe inflammatory activity (MHA) improve functional capacity (FC) after a comprehensive rehabilitation program. Methods Nested case-control study. RA patients who completed a rehabilitation program between June 2014 and December 2017 were included. The interventions were prescribed according to the rehabilitation team’s discretion. FC was assessed with Health Assessment Questionnaire Disability Index (HAQ) and compared between before and after interventions. The group which improved at least 50% in CDAI was compared to the group which achieved Results We included 46 patients with complete HAQ and baseline CDAI data, with a mean age of 53.6 years and mean disease duration of 11.8 years. HAQ and CDAI improved on average 0.481 (± 0.500) and 14.2 (± 16.7), respectively. Patients who improved CDAI tended to have a greater mean HAQ difference (0.6 vs. 0.3; p = 0.058). Conversely, patients who did not improve disease activity had a HAQ reduction of 0.3 (± 0.4). Post-hoc analysis was performed on the group of 9 patients with baseline CDAI ≤10. A mean baseline CDAI of 5.2 and a mean HAQ difference of 0.319 (0.079; 0.56; p = 0.016) were found. Conclusions After rehabilitation, RA patients with sustained MHA improved FC similarly to patients with baseline mild activity or remission. Thus, patients with RA and MHA may benefit from rehabilitation concurrently with drug treatment. This study suggests that the range of improvement in FC with rehabilitation appears to have an additive effect to the drug therapy.
- 1 October 2016
- Published by Elsevier in Gait & Posture
- Vol. 50, 96-101
Vitamin d is related to gait recovery after total hip arthroplasty: A prospective analysis
- 1 October 2016
- Published by Elsevier in Gait & Posture
- Vol. 50, 96-101
Vitamin d is related to gait recovery after total hip arthroplasty: A prospective analysis
- Open Access
- 1 September 2015
- Published by Springer Nature in Revista Brasileira de Reumatologia
- Vol. 55 (5) , 420-426
Coorte Sarar: atividade de doença, capacidade funcional e dano radiológico em pacientes com artrite reumatoide submetidos à artroplastia total de quadril e joelho
The Sarar cohort consists of patients with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) who underwent hip or knee arthroplasties at hospital Sarah-Brasília. The objective of this study was to evaluate clinical and laboratory factors associated with disease activity, functional capacity and radiological damage in RA patients, participants in this cohort. cross-sectional study, with data collection achieved from medical records review. Thirty-two patients were included, with a mean time of disease onset of 240 months. Nineteen patients underwenttotal knee (TKA) and 17 total hip (THA) arthroplasty. There was a positive correlation between maximum dose of methotrexate (MTX) and Clinical Disease Activity Index (CDAI) (R = -0.46, p = 0.011), and a negative one with Simplified Erosion and Narrowing Score (SENS) (R = - 0.58, p = 0.004). SENS values were higher in patients with rheumatoid factor (RF) (p = 0.005) and anti-cyclic citrullinated peptide antibody 3 (anti-CCP3) positivity (p = 0.044), in those with higher RF (p = 0.037) and anti-CCP3 (p = 0.025) titers, and lower in patients with family history of RA (p = 0.009). HAQ values were higher in older patients (p = 0.031). In multiple linear regression, only "maximum dose of MTX' and "family history" remained with significant association with SENS (r(2) = 0.73, p <0.001 for both variables). In the model evaluating CDAI only "maximum dose of MTX" remained significantly associated (r(2) = 0.35, p = 0.016). In the Sarar cohort, clinical and laboratory factors were related to disease activity, functional capacity and radiological damage, similar to studies evaluating patients with lower disease duration.
- 1 September 2015
- Published by Springer Nature in Revista Brasileira de Reumatologia
- Vol. 55 (5) , 420-426
Open AccessCoorte Sarar: atividade de doença, capacidade funcional e dano radiológico em pacientes com artrite reumatoide submetidos à artroplastia total de quadril e joelho
The Sarar cohort consists of patients with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) who underwent hip or knee arthroplasties at hospital Sarah-Brasília. The objective of this study was to evaluate clinical and laboratory factors associated with disease activity, functional capacity and radiological damage in RA patients, participants in this cohort. cross-sectional study, with data collection achieved from medical records review. Thirty-two patients were included, with a mean time of disease onset of 240 months. Nineteen patients underwenttotal knee (TKA) and 17 total hip (THA) arthroplasty. There was a positive correlation between maximum dose of methotrexate (MTX) and Clinical Disease Activity Index (CDAI) (R = -0.46, p = 0.011), and a negative one with Simplified Erosion and Narrowing Score (SENS) (R = - 0.58, p = 0.004). SENS values were higher in patients with rheumatoid factor (RF) (p = 0.005) and anti-cyclic citrullinated peptide antibody 3 (anti-CCP3) positivity (p = 0.044), in those with higher RF (p = 0.037) and anti-CCP3 (p = 0.025) titers, and lower in patients with family history of RA (p = 0.009). HAQ values were higher in older patients (p = 0.031). In multiple linear regression, only "maximum dose of MTX' and "family history" remained with significant association with SENS (r(2) = 0.73, p <0.001 for both variables). In the model evaluating CDAI only "maximum dose of MTX" remained significantly associated (r(2) = 0.35, p = 0.016). In the Sarar cohort, clinical and laboratory factors were related to disease activity, functional capacity and radiological damage, similar to studies evaluating patients with lower disease duration.
- 1 May 2015
- Published by Elsevier in Autoimmunity Reviews
- Vol. 14 (5) , 396-400
HIV/AIDS and rheumatoid arthritis
- 1 May 2015
- Published by Elsevier in Autoimmunity Reviews
- Vol. 14 (5) , 396-400
HIV/AIDS and rheumatoid arthritis
- 3 April 2012
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 13 (9) , 797
An unusual coronary to LV cavitary fistula in a young patient
- 3 April 2012
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 13 (9) , 797
An unusual coronary to LV cavitary fistula in a young patient
- Open Access
- 23 February 2012
- Published by Wiley in International Journal of Rheumatology
- Vol. 2012, 1-5
Risk of Orthopedic Surgical Site Infections in Patients with Rheumatoid Arthritis Treated with Antitumor Necrosis Factor Alfa Therapy
Introduction. International guidelines recommend interruption of anti-TNF medications in the perioperative period, but there are no randomized trials to support such recommendation.Objectives. To study literature evidence assessing the risk of surgical site infections in orthopedic surgery patients with RA using anti-TNF drugs, compared to untreated patients or those using conventional DMARD.Methods. Systematic review of cohort studies is concerning surgical site infections in orthopedic procedures in patients with RA.Results. Three studies were selected. Only one was considered of high-quality, albeit with low statistical power. The review resulted in inconclusive data, since the best quality study showed no significant differences between groups, while others showed increased risk of infections in patients using anti-TNF medications.Conclusion. It is unclear whether patients with RA using anti-TNF medications are at increased risk of surgical site infections. Randomized controlled trials or new high quality observational studies are needed to clarify the issue.
- 23 February 2012
- Published by Wiley in International Journal of Rheumatology
- Vol. 2012, 1-5
Open AccessRisk of Orthopedic Surgical Site Infections in Patients with Rheumatoid Arthritis Treated with Antitumor Necrosis Factor Alfa Therapy
Introduction. International guidelines recommend interruption of anti-TNF medications in the perioperative period, but there are no randomized trials to support such recommendation.Objectives. To study literature evidence assessing the risk of surgical site infections in orthopedic surgery patients with RA using anti-TNF drugs, compared to untreated patients or those using conventional DMARD.Methods. Systematic review of cohort studies is concerning surgical site infections in orthopedic procedures in patients with RA.Results. Three studies were selected. Only one was considered of high-quality, albeit with low statistical power. The review resulted in inconclusive data, since the best quality study showed no significant differences between groups, while others showed increased risk of infections in patients using anti-TNF medications.Conclusion. It is unclear whether patients with RA using anti-TNF medications are at increased risk of surgical site infections. Randomized controlled trials or new high quality observational studies are needed to clarify the issue.
- 1 December 2011
- Vol. 51 (6) , 609-15
Incidence of infectious complications in hip and knee arthroplasties in rheumatoid arthritis and osteoarthritis patients.
Rheumatoid arthritis (RA) is one of the major indications of total hip (THA) or knee (TKA) arthroplasty. International studies have suggested that RA is a risk factor for prosthesis infections. To compare patients with RA and patients with osteoarthritis (OA) of other etiologies with regard to the incidence of prosthesis, incisional, and other systemic postoperative infections in THA and TKA. Retrospective, comparative cohort of patients followed up after undergoing THA or TKA at the Hospital SARAH-Brasília, from 1996 to 2007. Seventy-five arthroplasties (28 TKA and 47 THA) were identified in RA patients. As controls, 131 surgeries (56 TKA and 75 THA) in OA patients were randomly selected and stratified by surgery and gender. No significant difference was observed between the RA and OA groups regarding the rates of prosthesis infections (TKA 7.1% vs. 0% and THA 2.1% vs. 0%, respectively, both with P > 0.1), incisional infections (TKA 14.3% vs. 3.3% and THA 4.3 vs. 1.3%, respectively, both with P > 0.1), and systemic infections (TKA 7.1% vs. 3.6%, P = 0.92 and THA 4.3% vs. 10.7%, P > 0.1, respectively). After multiple logistic regression, the results did not change. RA was not identified as a risk factor for perioperative infections in THA and TKA in this case series of the Hospital SARAH-Brasília, as compared with the group of patients with primary OA or OA secondary to non-inflammatory diseases. The low incidence of infections in both groups may explain our findings.
- 1 December 2011
- Vol. 51 (6) , 609-15
Incidence of infectious complications in hip and knee arthroplasties in rheumatoid arthritis and osteoarthritis patients.
Rheumatoid arthritis (RA) is one of the major indications of total hip (THA) or knee (TKA) arthroplasty. International studies have suggested that RA is a risk factor for prosthesis infections. To compare patients with RA and patients with osteoarthritis (OA) of other etiologies with regard to the incidence of prosthesis, incisional, and other systemic postoperative infections in THA and TKA. Retrospective, comparative cohort of patients followed up after undergoing THA or TKA at the Hospital SARAH-Brasília, from 1996 to 2007. Seventy-five arthroplasties (28 TKA and 47 THA) were identified in RA patients. As controls, 131 surgeries (56 TKA and 75 THA) in OA patients were randomly selected and stratified by surgery and gender. No significant difference was observed between the RA and OA groups regarding the rates of prosthesis infections (TKA 7.1% vs. 0% and THA 2.1% vs. 0%, respectively, both with P > 0.1), incisional infections (TKA 14.3% vs. 3.3% and THA 4.3 vs. 1.3%, respectively, both with P > 0.1), and systemic infections (TKA 7.1% vs. 3.6%, P = 0.92 and THA 4.3% vs. 10.7%, P > 0.1, respectively). After multiple logistic regression, the results did not change. RA was not identified as a risk factor for perioperative infections in THA and TKA in this case series of the Hospital SARAH-Brasília, as compared with the group of patients with primary OA or OA secondary to non-inflammatory diseases. The low incidence of infections in both groups may explain our findings.